Company Profile

Neuropathix, Inc. is a biopharmaceutical company. It is focused on discovering, developing, and commercializing novel therapeutics from its proprietary synthetic cannabinoid derivative platform that are potentially useful for a range of inflammatory and neuropathic pain-related diseases. Its product candidates include KLS-13019 and KLS-13023. KLS-13019 can control mechanical sensitivity and inflammation associated with chemotherapy-induced peripheral neuropathy (CIPN) in the absence of tolerance development and also reduce opioid craving behavior. KLS-13023 is a drug candidate that includes synthetic cannabidiol (CBD) formulated in a gel capsule designed for potential use in humans. Its drug discovery platform potentially treats neurological and oxidative stress-related disorders, such as overt hepatic encephalopathy (OHE), chronic traumatic encephalopathy (CTE), and CIPN, with current good manufacturing practices (cGMP) pharmaceutical grade semi-synthetic and synthetic cannabinoids.

Employees

Sector

Biotechnology & Medical Research

More about the company

18/11	Neuropathix, Inc. announced a financing transaction	CI
24/05/22	Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
15/04/22	Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
15/04/22	Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/03/22	Neuropathix, Inc. announced that it has received $0.15 million in funding	CI
13/11/21	Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
13/08/21	Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board	CI
07/08/21	Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
14/05/21	Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
31/03/21	Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
10/02/21	Neuropathix, Inc. announced that it has received $1.2075 million in funding from Lyons Capital, LLC	CI
13/01/21	Neuropathix, Inc. Appoints Daniel Richman to Board of Advisors	CI
13/11/20	Neuropathix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI

24/05/22	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
26/04/22	Neuropathix : OTC Certification - Neuropathix, Inc. - FYE 2021	PU
15/04/22	NEUROPATHIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
25/03/22	NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
13/11/21	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ

Manager	Title	Age	Since
Dean Petkanas CEO	Chief Executive Officer	47	25/07/2018
William Kinney CTO	Chief Tech/Sci/R&D Officer	68	25/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/1/22	Dean Petkanas	Sell	Chief Executive Officer	180,000	0.1981%
5/1/22	Dean Petkanas	Sell	Chief Executive Officer	800,000	0.8803%
5/1/22	Dean Petkanas	Sell	Chief Executive Officer	720,000	0.7923%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUROPATHIX, INC.	-.--%	-.--%	-	-	29.31K
ARGENX SE	-2.29%	-4.94%	+44.65%	+65.60%	55.2B
WUXI APPTEC CO., LTD.	+2.83%	+0.48%	+28.18%	+82.59%	55.6B
BIONTECH SE	+0.54%	+1.22%	-16.62%	-13.47%	23.51B
INSMED INCORPORATED	-0.97%	-3.30%	-1.79%	+383.00%	22.35B
WUXI BIOLOGICS (CAYMAN) INC.	-4.01%	-3.67%	+13.17%	-14.29%	20.6B
GENMAB A/S	-1.63%	-3.31%	+25.79%	-33.94%	17.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.34%	-7.77%	+23.78%	+536.66%	15.16B
EXELIXIS, INC.	-2.09%	+0.64%	+49.78%	+178.74%	13.91B
PHARMAESSENTIA CORPORATION	-3.14%	-8.47%	+165.37%	+292.18%	13.74B
Average	-1.43%	-1.27%	+36.92%	+164.12%	26.39B
Weighted average by Cap.	-0.93%	-0.52%	+32.20%	+127.18%

Neuropathix, Inc. Stock

Stocks

NPTX

US64132Q1094

Biotechnology & Medical Research

Latest news : Neuropathix, Inc.

Press Releases: Neuropathix, Inc.

Managers and Directors: Neuropathix, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile